Requests To Reopen Medicare ESA Policy Are Not Yet Persuasive To CMS
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency advises stakeholders that they must present new data or analysis that current data was materially misinterpreted in order to gain a reconsideration of the erythropoeisis-stimulating agents coverage policy.
You may also be interested in...
ASCO Updates ESA Treatment Guidelines
Recommendation made jointly with American Society of Hematology calls for maintaining hemoglobin levels above 10 g/dL.
ASCO Updates ESA Treatment Guidelines
Recommendation made jointly with American Society of Hematology calls for maintaining hemoglobin levels above 10 g/dL.
FDA Calls Medicare ESA Coverage Decision “Generally Consistent” With Labeling
FDA acknowledges confusion with dosing recommendations that it aims to clarify in revised labeling, agency advises Reps. Waxman and Stark.